Acadia says Alzheimer’s psychosis drug clears mid-stage study

(Reuters) – Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer’s disease met its main goal in a mid-stage study. Acadia shares rose as much as 18.5 percent to $30.14 in early trading on Tuesday. The company said the drug, pimavanserin, showed a statistically significant reduction in psychosis with a 3.76 point improvement in the sixth week, compared with 1.93 for placebo. …
Go to Source